Financial Data and Key Metrics Changes - The company's Q1 2021 revenues were $3.1 million, an increase of 83% compared to $1.7 million in Q1 2020, reflecting a recovery from the pandemic's impact [5][20] - Gross profit for Q1 2021 was $1.6 million, representing 51.7% of revenue, up from $0.7 million or 42.2% in the prior year [21] - The net loss for Q1 2021 was $1.1 million or $0.07 per share, compared to a net loss of $3.6 million or $0.22 per share in Q1 2020 [22] Business Line Data and Key Metrics Changes - The company shipped 7 SRT systems in Q1 2021, including 6 domestic sales and 1 to China, indicating a positive trend in sales [5][20] - The reimbursement environment improved significantly, with increases of up to 50% over previous years for SRT users due to new coding [7][8] Market Data and Key Metrics Changes - The company has only penetrated about 2% of the U.S. market, indicating substantial growth potential [8] - Business in China is promising, with additional sales expected following the engagement of a new distribution partner [16] Company Strategy and Development Direction - The company is focusing on educating the market about new reimbursement codes and plans to continue this effort throughout 2021 [7][38] - There is an emphasis on expanding the Mobile Aesthetic Laser business beyond Florida, targeting markets like Dallas, Atlanta, and Scottsdale [42] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about continued revenue growth as economic activity improves post-COVID [5][26] - The company is preparing for a significant marketing push for aesthetic lasers, particularly at upcoming industry symposiums [36][27] Other Important Information - The company has developed a fair market value lease program to make higher-priced products more accessible to customers [9] - The Sculptura system received a U.S. patent, which could open new opportunities for radiation therapy applications [17][18] Q&A Session Summary Question: Do you expect any seasonality in terms of sales SRT systems? - Management indicated uncertainty due to economic conditions in China but hopes for additional orders before the license renewal in November [30] Question: What is the current operating capacity of dermatologist offices in the U.S.? - Management estimated that offices are operating at about 80% to 90% of pre-COVID levels, with stronger recovery in states like Florida and Texas [34] Question: Will sales of aesthetic lasers significantly contribute to revenue this year? - Management expects aesthetic lasers to contribute to sales but not significantly, with a marketing push planned for the second quarter [36] Question: What steps have been taken to educate the market about reimbursement changes? - Management conducted Zoom meetings with over 100 physicians to discuss new reimbursement codes and plans to continue these efforts [38][39] Question: What is the status of the sales force and expansion plans? - The sales force is nearly back to pre-COVID levels, with aggressive hiring planned to support growth in the second half of the year [41] Question: What territories are being targeted for the Mobile Aesthetic business expansion? - Management identified Dallas, Atlanta, and Scottsdale as key markets for expansion [42] Question: Any updates on the Sculptura system sales discussions? - Management remains optimistic about future sales, despite the pandemic's impact on hospital operations [47][49]

Part I [Item 1. Business](index=5&type=section&id=Item%201.%20Business) Sensus Healthcare specializes in superficial radiation therapy for skin conditions, expanding into broader cancer treatment and aesthetic lasers, with revenue from product sales and services, subject to extensive regulation [Overview and Products](index=5&type=section&id=Overview%20and%20Products) Sensus Healthcare offers non-invasive SRT for skin conditions, including the SRT-100 series, Sculptura™ for cancer, and aesthetic laser rental services - The company's core business is providing non-invasive treatments for skin conditions using its proprietary **superficial radiation therapy (SRT)** technology[20](index=20&type=chunk) - Key products include the **SRT-100, SRT-100+, and SRT-100 Vision**, used to treat non-melanoma skin cancers and keloids[22](index=22&type=chunk)[24](index=24&type=chunk)[25](index=25&type=chunk) - The company expanded its offerings with the **FDA-cleared Sculptura™**, a robotic brachytherapy system for intraoperative cancer treatment[25](index=25&type=chunk) - In August 2020, Sensus acquired two mobile aesthetic laser companies to form **Sensus Laser Aesthetic Solutions (SLAS)**, expanding into the aesthetic laser rental market in Florida[27](index=27&type=chunk) [Sales, Marketing, and Manufacturing](index=7&type=section&id=Sales%2C%20Marketing%2C%20and%20Manufacturing) Sensus uses a direct U.S. sales force and international distributors to target dermatologists and radiation oncologists, with manufacturing outsourced to a third party - The company targets private dermatology practices and radiation oncologists using a **direct U.S. sales force** and **international distributors**[33](index=33&type=chunk) - As of December 31, 2020, Sensus had an installed base of **491 units** in **18 countries**, primarily in the United States[38](index=38&type=chunk) - Manufacturing of SRT-100 products is outsourced to **RbM Services, LLC**, under a renewable one-year agreement[39](index=39&type=chunk) - The company relies on a **single preferred supplier** for x-ray tubes and other major components, but alternate suppliers are believed to be available[42](index=42&type=chunk) [Intellectual Property and Government Regulation](index=8&type=section&id=Intellectual%20Property%20and%20Government%20Regulation) The company protects its technology with patents and is subject to extensive FDA and international regulations, including Class II device classification and compliance with healthcare laws - The company holds several issued U.S. and global patents, with **22 patent applications pending** as of December 31, 2020[43](index=43&type=chunk)[45](index=45&type=chunk) - Sensus's medical devices are classified as **Class II devices** by the FDA and have obtained all clearances through the **510(k) pathway**[52](index=52&type=chunk)[54](index=54&type=chunk) - The company has obtained approval to sell products in numerous international markets, including **China** and the **EU/EEA**, requiring separate regulatory compliance like the CE mark[57](index=57&type=chunk)[58](index=58&type=chunk)[60](index=60&type=chunk) Regulatory Compliance Expenses | Year | Expenses (USD) | | :--- | :--- | | 2020 | ~$1.3 million | | 2019 | ~$1.6 million | [Research & Development and Human Capital](index=14&type=section&id=Research%20%26%20Development%20and%20Human%20Capital) R&D expenses decreased to $4.2 million in 2020 due to Sculptura™ development completion, and the company had 42 employees as of December 31, 2020 Research and Development Expenses | Year | R&D Expense (USD) | | :--- | :--- | | 2020 | ~$4.2 million | | 2019 | ~$6.4 million | - The decrease in R&D spending from 2019 to 2020 was primarily related to the final development and production ramp-up of the **Sculptura™ system**[71](index=71&type=chunk) - As of December 31, 2020, the company had **42 employees**, none represented by a labor union[72](index=72&type=chunk) [Item 1A. Risk Factors](index=15&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant risks from reimbursement dependence, COVID-19, single product reliance, customer concentration, supply chain issues, regulatory compliance, and intellectual property disputes [Business and Financial Risks](index=15&type=section&id=Business%20and%20Financial%20Risks) Key risks include dependence on third-party reimbursement, COVID-19 impact, reliance on the SRT-100 product line, significant customer and geographic concentration, and single supplier reliance - Commercial success is highly dependent on coverage and adequate reimbursement from **governmental and private payors** for procedures using the company's products[78](index=78&type=chunk) - The **COVID-19 pandemic** has negatively impacted sales due to physician practice closures and social distancing, with its future impact remaining uncertain[81](index=81&type=chunk)[82](index=82&type=chunk) - The company has significant customer and geographic concentration, with one U.S. customer accounting for **39% of 2020 revenues** and **91% of 2020 sales** originating in the U.S.[86](index=86&type=chunk) - The company has a history of net losses, totaling approximately **$21.9 million** from inception through December 31, 2020[110](index=110&type=chunk) [Regulatory and Legal Risks](index=18&type=section&id=Regulatory%20and%20Legal%20Risks) Sensus is subject to complex healthcare laws, including Anti-Kickback Statute and HIPAA, with non-compliance risking penalties, recalls, and adverse impacts from policy changes - The company is subject to numerous healthcare laws, including the federal **Anti-Kickback Statute**, **False Claims Act**, and **HIPAA**, with non-compliance potentially leading to significant penalties[94](index=94&type=chunk)[95](index=95&type=chunk)[97](index=97&type=chunk) - Sensus must report certain device-related malfunctions, deaths, and serious injuries to the **FDA** and other international bodies, which could result in recalls or fines[98](index=98&type=chunk)[99](index=99&type=chunk) - Changes in healthcare policy and reimbursement rates from programs like **Medicare** could have a material adverse effect on the company's revenue and profitability[100](index=100&type=chunk)[101](index=101&type=chunk) [Intellectual Property and Ownership Risks](index=20&type=section&id=Intellectual%20Property%20and%20Ownership%20Risks) Risks include inadequate intellectual property protection, costly patent litigation, a history of net losses, stock price volatility, no dividends, reduced disclosure as an emerging growth company, and significant insider ownership - The company's ability to protect its proprietary technology through **patents and other IP rights** is critical, but these may not be sufficient to prevent competition or withstand legal challenges[103](index=103&type=chunk)[105](index=105&type=chunk) - The company is an **'emerging growth company'** and a **'smaller reporting company'**, allowing for reduced public reporting and disclosure requirements[116](index=116&type=chunk)[119](index=119&type=chunk) - Executive officers and directors beneficially owned approximately **19% of outstanding common stock** as of February 8, 2021, allowing substantial influence over corporate matters[120](index=120&type=chunk) - The company does not anticipate paying dividends in the foreseeable future, meaning investors must rely on **stock price appreciation** for returns[112](index=112&type=chunk) [Item 1B. Unresolved Staff Comments](index=25&type=section&id=Item%201B.%20Unresolved%20Staff%20Comments) The company has no unresolved comments from the SEC staff regarding its periodic or current reports - As of the filing date, Sensus Healthcare has no unresolved comments from the SEC staff[129](index=129&type=chunk) [Item 2. Properties](index=25&type=section&id=Item%202.%20Properties) Sensus Healthcare's corporate headquarters is a leased facility in Boca Raton, Florida, with manufacturing outsourced to a third-party in Tennessee - The company's corporate headquarters is in a leased space of **8,926 sq. ft.** in Boca Raton, Florida, with the lease expiring in September 2022[130](index=130&type=chunk) - The main manufacturing function is physically located at the third-party manufacturer's facility in Oak Ridge, Tennessee[130](index=130&type=chunk) [Item 3. Legal Proceedings](index=25&type=section&id=Item%203.%20Legal%20Proceedings) The company is involved in ordinary course legal proceedings, which management does not expect to materially impact financial results - Management does not anticipate that current legal proceedings will have a material impact on the company's financial results[131](index=131&type=chunk) [Item 4. Mine Safety Disclosure](index=25&type=section&id=Item%204.%20Mine%20Safety%20Disclosure) This item is not applicable to the company - Not applicable[132](index=132&type=chunk) Part II [Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=26&type=section&id=Item%205.%20Market%20for%20Registrant%27s%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) The company's common stock trades on NASDAQ, has 24 stockholders, and does not anticipate paying dividends, retaining earnings for growth - The company's common stock is traded on the **NASDAQ Capital Market** under the symbol **'SRTS'**[135](index=135&type=chunk) - Sensus has never declared or paid a dividend and does not plan to in the foreseeable future, citing the need to retain earnings for growth[136](index=136&type=chunk) [Item 6. Selected Financial Data](index=26&type=section&id=Item%206.%20Selected%20Financial%20Data) This item is not applicable as the company is a smaller reporting company - Not applicable[139](index=139&type=chunk) [Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=26&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the significant COVID-19 impact on 2020 sales, leading to decreased revenues and increased net loss, partially offset by expense reductions and liquidity measures [Impact of COVID-19](index=27&type=section&id=Impact%20of%20COVID-19) The COVID-19 pandemic significantly impacted 2020 sales due to physician practice closures, and its future effects on the business remain uncertain - The **COVID-19 pandemic** significantly impacted the company's sales in 2020 as social distancing measures forced physicians to temporarily close their practices[144](index=144&type=chunk) - The future impact of the pandemic on the company's business, operations, and financial condition is **uncertain** and cannot be reasonably estimated[144](index=144&type=chunk) [Results of Operations (2020 vs. 2019)](index=27&type=section&id=Results%20of%20Operations%20(2020%20vs.%202019)) In 2020, revenues decreased by 64.9% to $9.6 million due to COVID-19, leading to a wider net loss despite reduced operating expenses Consolidated Results of Operations (in thousands) | Metric | 2020 | 2019 | | :--- | :--- | :--- | | Revenues | $9,577 | $27,263 | | Gross Profit | $5,249 | $17,557 | | Loss from Operations | ($8,234) | ($1,968) | | Net Loss | ($6,836) | ($1,700) | - Revenues decreased by **$17.7 million** in 2020, primarily due to the impact of COVID-19, which restricted sales activities[147](index=147&type=chunk) - Selling and marketing expenses decreased by **$3.8 million (41.4%)** due to trade show cancellations and lower commission, while R&D expenses decreased by **$2.3 million (35.2%)** as the Sculptura project entered its production phase[150](index=150&type=chunk) - Other income increased significantly in 2020, driven by a **$757,782 gain** from the forgiveness of a PPP loan and a **$588,011 bargain purchase gain** from acquisitions[151](index=151&type=chunk) [Liquidity and Capital Resources](index=28&type=section&id=Liquidity%20and%20Capital%20Resources) Cash and equivalents slightly decreased to $14.9 million in 2020, with improved operating cash flow and increased investing cash flow from matured investments Summary of Cash Flows (in thousands) | Activity | 2020 | 2019 | | :--- | :--- | :--- | | Net cash used in Operating | ($434) | ($2,107) | | Net cash from (used in) Investing | $7,031 | ($4,898) | | Net cash from Financing | $210 | $2,620 | - The company's cash and cash equivalents balance increased to **$14.9 million** at year-end 2020 from **$8.1 million** at year-end 2019, primarily due to matured investments[152](index=152&type=chunk)[179](index=179&type=chunk) - In 2020, the company obtained a **PPP loan of $1,022,785** to bolster liquidity amid the pandemic[154](index=154&type=chunk) - Management believes existing capital resources are **sufficient** to meet operating and funding requirements for at least the next 12 months[156](index=156&type=chunk) [Item 7A. Quantitative and Qualitative Disclosures About Market Risk](index=31&type=section&id=Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This item is not applicable as the company is a smaller reporting company - Not applicable[169](index=169&type=chunk) [Item 8. Financial Statements and Supplementary Data](index=32&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) This section presents the company's audited consolidated financial statements for 2020 and 2019, including balance sheets, income statements, equity, cash flows, and notes [Financial Statements](index=33&type=section&id=Financial%20Statements) The audited financial statements show total assets decreased to $28.0 million in 2020, with a net loss of $6.8 million, and a net increase in cash and equivalents Key Balance Sheet Data (in thousands) | Metric | Dec 31, 2020 | Dec 31, 2019 | | :--- | :--- | :--- | | Cash and cash equivalents | $14,907 | $8,100 | | Total Current Assets | $25,171 | $34,003 | | Total Assets | $28,010 | $36,925 | | Total Liabilities | $6,514 | $8,923 | | Total Stockholders' Equity | $21,496 | $28,001 | Net Loss Per Share | Year | Basic and Diluted EPS | | :--- | :--- | | 2020 | ($0.42) | | 2019 | ($0.10) | [Notes to Financial Statements](index=38&type=section&id=Notes%20to%20Financial%20Statements) Notes detail accounting policies, the COVID-19 impact, a 2020 acquisition gain, PPP loan forgiveness, and a pending Department of Justice investigation - One U.S. customer accounted for approximately **40% of revenue in 2020** and **68% in 2019**[203](index=203&type=chunk) - On August 3, 2020, the company acquired two mobile aesthetic laser companies, resulting in a **bargain purchase gain of $588,011**[226](index=226&type=chunk)[227](index=227&type=chunk)[228](index=228&type=chunk) - In April 2020, the company received a **PPP loan of $1,022,785**, of which **$757,782** was subsequently forgiven[235](index=235&type=chunk) - The company is cooperating with a **Department of Justice investigation** concerning Medicare billing by a physician who used an SRT-100 device, disputing wrongdoing and unable to estimate potential costs[244](index=244&type=chunk) [Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure](index=51&type=section&id=Item%209.%20Changes%20in%20and%20Disagreements%20with%20Accountants%20on%20Accounting%20and%20Financial%20Disclosure) The company reports no disagreements with its accountants regarding accounting principles, financial disclosure, or auditing scope - There have been no disagreements on accounting and financial disclosure matters with the company's accountants[263](index=263&type=chunk) [Item 9A. Controls and Procedures](index=51&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and internal control over financial reporting were effective as of December 31, 2020 - Management concluded that the company's disclosure controls and procedures were effective as of December 31, 2020[264](index=264&type=chunk) - Management concluded that internal control over financial reporting was effective as of December 31, 2020[265](index=265&type=chunk) [Item 9B. Other Information](index=51&type=section&id=Item%209B.%20Other%20Information) No other information is being furnished in this report - No other information is being furnished[268](index=268&type=chunk) Part III [Item 10. Directors, Executive Officers, and Corporate Governance](index=52&type=section&id=Item%2010.%20Directors%2C%20Executive%20Officers%2C%20and%20Corporate%20Governance) Information on directors, executive officers, and corporate governance is incorporated by reference from the 2021 Proxy Statement - Information is incorporated by reference from the 2021 Proxy Statement[271](index=271&type=chunk) [Item 11. Executive Compensation](index=52&type=section&id=Item%2011.%20Executive%20Compensation) Information on executive compensation is incorporated by reference from the 2021 Proxy Statement - Information is incorporated by reference from the 2021 Proxy Statement[272](index=272&type=chunk) [Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](index=52&type=section&id=Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholder%20Matters) This section details equity compensation plans and incorporates security ownership information by reference from the 2021 Proxy Statement Equity Compensation Plan Information | Plan Category | Securities to be issued upon exercise of outstanding options, warrants and rights | Weighted-average exercise price | Securities remaining available for future issuance | | :--- | :--- | :--- | :--- | | Approved by Security Holders | 229,334 | $5.55 | 265,973 | [Item 13. Certain Relationships and Related Transactions, and Director Independence](index=52&type=section&id=Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions%2C%20and%20Director%20Independence) Information on related party transactions and director independence is incorporated by reference from the 2021 Proxy Statement - Information is incorporated by reference from the 2021 Proxy Statement[275](index=275&type=chunk) [Item 14. Principal Accountant Fees and Services](index=52&type=section&id=Item%2014.%20Principal%20Accountant%20Fees%20and%20Services) Information on principal accountant fees and services is incorporated by reference from the 2021 Proxy Statement - Information is incorporated by reference from the 2021 Proxy Statement[276](index=276&type=chunk) Part IV [Item 15. Exhibits and Financial Statement Schedules](index=53&type=section&id=Item%2015.%20Exhibits%20and%20Financial%20Statement%20Schedules) This section lists all exhibits and financial statement schedules filed with the Form 10-K report - This section includes the company's consolidated financial statements and a list of all exhibits filed with the report[278](index=278&type=chunk) [Item 16. Form 10-K Summary](index=53&type=section&id=Item%2016.%20Form%2010-K%20Summary) The company has not provided a summary for its Form 10-K - None provided[279](index=279&type=chunk)

FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-37714 Sensus Healthcare, Inc. (Exact name of registrant as specified in its charter) | Delaware | 27-1647271 ...

Sensus Healthcare, Inc. (NASDAQ:SRTS) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Kim Golodetz - SVP and Principal, Lippert/Heilshorn & Associates, Inc. Joe Sardano - CEO Javier Rampolla - CFO Conference Call Participants Benjamin Haynor - Alliance Global Scott Henry - ROTH Capital James Terwilliger - Northland Capital Markets Anthony Vendetti - Maxim Group Operator Good day, ladies and gentlemen, and welcome to your Sensus Healthcare Conference Call [Operator Instructi ...

For the transition period from ____________ to ____________ Commission File Number: 001-37714 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Sensus Healthcare, Inc. (Exact name of registrant as specified in its charter) | Delaware | 27-1647271 | | ...

Sensus Healthcare, Inc. (NASDAQ:SRTS) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants Kim Golodetz – Senior Vice President and Principal-Lippert/Heilshorn & Associates, Inc. Joe Sardano – Chief Executive Officer Javier Rampolla – Chief Financial Officer Conference Call Participants Will Fafinski – Craig-Hallum Capital Group Scott Henry – ROTH Capital James Terwilliger – Northland Capital Markets Boobalan Pachaiyappan – H.C. Wainwright Operator Good day, ladies and gentlemen, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-37714 Sensus Healthcare, Inc. (Exact name of registrant as specified in its charter) | Delaware | 27-1647271 | | ...

Sensus Healthcare, Inc. (NASDAQ:SRTS) Q1 2020 Earnings Conference Call May 7, 2020 4:30 PM ET Company Participants Kim Golodetz - Senior Vice President & Principal-LHA Joe Sardano - Chief Executive Officer Javier Rampolla - Chief Financial Officer Conference Call Participants Andrew D'Silva - B. Riley Scott Henry - ROTH Capital Anthony Vendetti - Maxim Group Operator Good day, ladies and gentlemen, and welcome to the Sensus Healthcare First Quarter 2020 Conference Call. All lines have been placed on a liste ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ____________ TO ____________ Commission File Number: 001-37714 Sensus Healthcare, Inc. (Exact name of registrant as specified in its charter) | Delaware | 27-1647271 | | --- ...

Sensus Healthcare, Inc. (NASDAQ:SRTS) Q4 2019 Earnings Conference Call February 13, 2020 4:30 PM ET Company Participants Kim Golodetz – Senior Vice President and Principal-LHA Joe Sardano – Chief Executive Officer Javier Rompolla – Chief Financial Officer Conference Call Participants Alex Nowak – Craig-Hallum Capital Scott Henry – ROTH Capital Andrew D’Silva – B. Riley Anthony Vendetti – Maxim Group Ben Haynor – Alliance Global Partners Yi Chen – H.C. Wainwright Operator Good day, ladies and gentlemen, and ...